JOÃO AUGUSTO MOURA

JOÃO AUGUSTO MOURA

(Fonte: Lattes)

ORCID

ScopusID

Resumo

Possui graduação em Tecnologia em saúde pela Faculdade de Tecnologia de Sorocaba (2005). Mestrado em Tecnologia Nuclear pela Universidade de São Paulo (2009). Doutorado em Tecnologia Nuclear pela Universidade de São Paulo (2015). Tem experiência na área de Tecnologia Nuclear, com ênfase em produção de fontes para radioterapia. Atualmente trabalha em pesquisa e desenvolvimento no Instituto de Pesquisas Energéticas e Nucleares (IPEN/CNEN-SP). (Texto extraído do Currículo Lattes em 8 maio 2023)

Lattes

Página do item completo

Resultados de Busca

Agora exibindo 1 - 4 de 4

New methodology for binding Iodine-125 onto silver for brachytherapy sources manufacture
2017 - SOUZA, C.D. de; ROSTELATO, M.C.M.; CARDOSO, R.M.; ARAKI, K.; MOURA, J.
Purpose: Cancer is a major health care problem in Brazil and the world. The Brazil’s National Institute for Cancer estimates around 60,000 new prostate cancer cases for 2017. We are assembling a laboratory for production of iodine-125 sources used in prostate brachytherapy in Brazil, since the imported treatment is extremely expensive, thus only available in the private healthcare sector. There are several challenges when developing a laboratory to produce radioactive sources. From choosing a prototype to radiation safety, the task is enormous. The whole production line is full of new process and innovations. Among those, a new chemical reaction that deposit iodine-125 onto silver (core) was developed. This paper presents a new reaction for binding iodine-125 into a silver core. The fixation percentage was calculated by measuring the activity in an ionization chamber. This methodology will be implemented at the iodine-125 sources manufacture laboratory. Methods: Silver cores are washed with an etching solution (100% sulfuric acid) for 5 minutes with sonication. The cores were then placed in sodium sulfate for at least 3 days. They went from a silver matte to a black color. The reaction was allowed to proceed overnight. Each core was individually measured. Results: The yield was 69.2% 7.1%. Considering the silver attenuation is around 20% the results were consider satisfactory. Conclusion: By maximize the reaction yield, we will be able to generate a less costly product that will be available through our public healthcare.
Brazil radioactive sources production for cancer treatment
2016 - ROSTELATO, MARIA E.; SOUZA, CARLA D.; ZEITUNI, CARLOS A.; MOURA, JOAO A.; MARQUES, JOSE R.O.; COSTA, OSVALDO L.; FEHER, ANSELMO; RODRIGUES, BRUNA T.; SOUZA, DAIANE C.B. de; PELEIAS JUNIOR, FERNANDO S.; SORGATTI, ANDERSON; MOSCA, RODRIGO; MOURA, EDUARDO S. de; ABREU, RODRIGO T.; SOUZA, RAQUEL V. DE; NOGUEIRA, BEATRIZ R.
The modality, known as brachytherapy, was performed in Brazil by only a hand full of hospitals at an extremely high cost. For producing new sources, five major areas must be considered: 1) source production: nuclear activation and/or radiochemical reaction; 2) welding; 3) Quality control: leakage tests; 4) Dosimetry and metrology; 5) Operational procedures; 6) validation studies. To perform all steps, a multidisciplinary team works together to overcome difficulties. - Iridium-192 pellets: In Brazil there are 140 machines with pellets that replacement every 5 years. Our new production line has assembly, welding and quality control hot cells. - Iridium-192 wires: Produced since 1999. The wire is activated at IPENs IEA-R1 reactor for 30 hours with 5x1013 n/cm-2.s-1 neutron flux resulting in 192 mCi maximum activity. - Iridium-192 seed: New seed for ophthalmic cancer treatment. The irradiation device presented 90% activity homogeneity. We are still testing in-vivo. - Iodine-125 seeds: Largely used in low dose brachytherapy. I-125 binding yield achieved with our new reaction was 80%; Laser welding presented 70% efficiency. Approved in all leakage tests. - Other ongoing projects: Veterinary brachytherapy, Waste management, Radionecrosis healing with laser, calibrations sources production, linear accelerator calculations for hospitals, sources with polymeric matrix Our Iodine-125 seeds will be available in 2018. All other projects are advancing. We will continue to develop new products hoping to help the Brazilian population fight against cancer. For producing new sources, five major areas must be considered: 1) source production: nuclear activation and/or radiochemical reaction; 2) welding; 3) Quality control:eakage tests; 4) Dosimetry and metrology; 5) Operational procedures; 6) validation studies. To perform all steps, a multidisciplinary team works together to overcome difficulties
Study and development of a iridium-192 seed for use in ophthalmic cancer
2014 - ROSTELATO, M.; SOUZA, C. de; PELEIAS JUNIOR, F.S.; ZEITUNI, C.A.; MATTOS, F.R.; BENEGA, M.A.G.; MOURA, J.A.; FEHER, A.; COSTA, O.L.
Comparison between the use loose and polymer string seeds in prostatic brachytherapy in Brazil
2014 - MOURA, E.; SOUZA, C. de; PELEIAS JUNIOR, F.S.; ZEITUNI, C.A.; ROSTELATO, M.E.C.M.; MATTOS, F.R.; BENEGA, M.A.G.; MOURA, J.A.; FEHER, A.; COSTA, A.L.